AREDYLD syndrome: Difference between revisions
CSV import |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Infobox medical condition | |||
| name = AREDYLD syndrome | |||
| image = [[File:Autosomal_recessive_-_en.svg|200px]] | |||
| caption = AREDYLD syndrome is inherited in an [[autosomal recessive]] pattern. | |||
| synonyms = [[Anemia]], [[Retarded development]], [[Dysmorphic facies]], [[Endocrinopathy]], [[Deafness]], [[Y-linked]] [[Lymphangiectasia]], [[Diabetes mellitus]] | |||
| specialty = [[Medical genetics]] | |||
| symptoms = Anemia, developmental delay, distinctive facial features, hormonal imbalances, hearing loss, lymphatic abnormalities, diabetes | |||
| onset = [[Infancy]] | |||
| duration = [[Lifelong]] | |||
| causes = [[Genetic mutation]] | |||
| risks = Family history of the condition | |||
| diagnosis = [[Genetic testing]], [[Clinical evaluation]] | |||
| differential = Other genetic syndromes with similar features | |||
| treatment = [[Symptomatic treatment]], [[Hormone replacement therapy]], [[Hearing aids]] | |||
| prognosis = Variable, depending on severity of symptoms | |||
| frequency = Rare | |||
}} | |||
[[File:Autosomal recessive - en.svg|thumb|Autosomal recessive - en|right]]<br>'''AREDYLD syndrome''' is a rare [[genetic disorder]] characterized by a combination of [[anemia]], [[reticulocytosis]], and [[dyskeratosis]]. The name AREDYLD is an acronym derived from these primary symptoms: Anemia, Reticulocytosis, and Dyskeratosis. | [[File:Autosomal recessive - en.svg|thumb|Autosomal recessive - en|right]]<br>'''AREDYLD syndrome''' is a rare [[genetic disorder]] characterized by a combination of [[anemia]], [[reticulocytosis]], and [[dyskeratosis]]. The name AREDYLD is an acronym derived from these primary symptoms: Anemia, Reticulocytosis, and Dyskeratosis. | ||
==Presentation== | ==Presentation== | ||
Revision as of 23:03, 31 March 2025
| AREDYLD syndrome | |
|---|---|
| Error creating thumbnail: | |
| Synonyms | Anemia, Retarded development, Dysmorphic facies, Endocrinopathy, Deafness, Y-linked Lymphangiectasia, Diabetes mellitus |
| Pronounce | N/A |
| Specialty | Medical genetics |
| Symptoms | Anemia, developmental delay, distinctive facial features, hormonal imbalances, hearing loss, lymphatic abnormalities, diabetes |
| Complications | N/A |
| Onset | Infancy |
| Duration | Lifelong |
| Types | N/A |
| Causes | Genetic mutation |
| Risks | Family history of the condition |
| Diagnosis | Genetic testing, Clinical evaluation |
| Differential diagnosis | Other genetic syndromes with similar features |
| Prevention | N/A |
| Treatment | Symptomatic treatment, Hormone replacement therapy, Hearing aids |
| Medication | N/A |
| Prognosis | Variable, depending on severity of symptoms |
| Frequency | Rare |
| Deaths | N/A |
AREDYLD syndrome is a rare genetic disorder characterized by a combination of anemia, reticulocytosis, and dyskeratosis. The name AREDYLD is an acronym derived from these primary symptoms: Anemia, Reticulocytosis, and Dyskeratosis.
Presentation
Individuals with AREDYLD syndrome typically present with symptoms related to anemia, such as fatigue, pallor, and shortness of breath. The reticulocytosis indicates an increased number of reticulocytes in the blood, which are immature red blood cells. Dyskeratosis refers to abnormal keratinization of the skin, leading to skin abnormalities such as hyperpigmentation, nail dystrophy, and oral leukoplakia.
Genetics
AREDYLD syndrome is believed to be inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the defective gene, one from each parent, to manifest the disease. The specific gene or genes involved in AREDYLD syndrome have not been definitively identified.
Diagnosis
Diagnosis of AREDYLD syndrome is based on clinical evaluation, detailed patient history, and laboratory tests. Blood tests typically reveal anemia and reticulocytosis. A skin biopsy may be performed to confirm dyskeratosis. Genetic testing can be used to identify mutations associated with the syndrome.
Treatment
There is no cure for AREDYLD syndrome, and treatment is primarily supportive. Management of anemia may include blood transfusions and iron supplementation. Skin abnormalities may be treated with topical medications and other dermatological interventions. Regular monitoring and supportive care are essential to manage the symptoms and improve the quality of life for affected individuals.
Prognosis
The prognosis for individuals with AREDYLD syndrome varies depending on the severity of the symptoms and the effectiveness of the supportive treatments. Early diagnosis and comprehensive management can improve outcomes and quality of life.
See also
References
<references group="" responsive="1"></references>
External links
-
